<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252733</url>
  </required_header>
  <id_info>
    <org_study_id>D2453C00045</org_study_id>
    <secondary_id>DIRECT</secondary_id>
    <secondary_id>SH-AHM-0045</secondary_id>
    <nct_id>NCT00252733</nct_id>
  </id_info>
  <brief_title>Diabetic Retinopathy Candesartan Trials</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether candesartan, compared to placebo reduces the
      incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients
      without retinopathy.

      The secondary objective is to determine whether candesartan, compared to placebo,
      beneficially influences the rate of change in urinary albumin excretion rate (UAER).

      This study is part of the DIRECT Programme also including secondary prevention studies of
      diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three
      pooled studies is to determine whether candesartan, compared to placebo, reduces the
      incidence of microalbuminuria in type 1 and type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.</measure>
    <time_frame>From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.</time_frame>
    <description>Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Urinary Albumin Excretion Rate (UAER).</measure>
    <time_frame>From baseline to end of study, i.e. 5 years.</time_frame>
    <description>An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5238</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>candesartan cilexetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan cilexetil</intervention_name>
    <description>32 mg once daily oral tablet given over 60 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ATACAND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin
             treatment within 1 year of diagnosis of diabetes are included.

          -  Duration of diabetes for &gt; 1 year and &lt; 15 years with stable diabetic therapy within
             last 6 months.

          -  Patients with untreated resting mean sitting SBP &lt; 130 mmHg, mean sitting DBP &lt; 85
             mmHg and with retinal photograph grading level 10/10 (on ETDRS severity scale).

        Exclusion Criteria:

          -  Patients with the following conditions are excluded from participation in the study:

          -  Cataract or media opacity of a degree which precludes taking gradable retinal
             photographs

          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil

          -  History of retinopathy

          -  History or presence of clinical significant macular oedema (CSME)

          -  History or evidence of photocoagulation of the retina Other retinal conditions which
             may mask assessment, eg, retinal vein occlusion

          -  Positive micral dipstick test

          -  Presence of secondary diabetes

          -  Pregnant or lactating women or women of child bearing potential not practicing an
             adequate method of contraception

          -  Need of treatment with ACE-inhibitor

          -  Haemodynamically significant aortic or mitral valve stenosis

          -  Known renal artery stenosis or kidney transplantation

          -  Hypersensitivity to study drug

          -  Severe concomitant disease which may interfere with the assessment of the patient, eg,
             malignancy, as judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Atacand Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=308&amp;filename=CSR-D2453C00045.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=308&amp;filename=CSR-D2453C00045.pdf</url>
    <description>CSR-D2453C00045.pdf</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>March 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2012</results_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Insulin-Dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled in the DIRECT Programme 8 June 2001 and last subject completed the DIRECT Programme 16 April 2008 mainly in hospital based clinics. 4514 patients type 1 diabetes were enrolled of whom 1421 proceeded to randomization, 711 to the candesartan arm and 710 to the placebo arm.</recruitment_details>
      <pre_assignment_details>The most common reason for not being randomized was that all eligibility criteria were not fulfilled, followed by withdrawn informed consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Candesartan</title>
          <description>Candesartan cilexetil 32 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="711"/>
                <participants group_id="P2" count="710"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="605"/>
                <participants group_id="P2" count="618"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple Reasons</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Candesartan</title>
          <description>Candesartan cilexetil 32 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="711"/>
            <count group_id="B2" value="710"/>
            <count group_id="B3" value="1421"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.60" spread="8.0"/>
                    <measurement group_id="B2" value="29.90" spread="8.1"/>
                    <measurement group_id="B3" value="29.75" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="318"/>
                    <measurement group_id="B3" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.</title>
        <description>Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments.</description>
        <time_frame>From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.</time_frame>
        <population>The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Candesartan</title>
            <description>Candesartan cilexetil 32 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.</title>
          <description>Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments.</description>
          <population>The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="711"/>
                <count group_id="O2" value="710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" spread="0.071"/>
                    <measurement group_id="O2" value="217" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0508</p_value>
            <method>Log Rank</method>
            <method_desc>Generalized</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.821</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>1.001</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Urinary Albumin Excretion Rate (UAER).</title>
        <description>An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient.</description>
        <time_frame>From baseline to end of study, i.e. 5 years.</time_frame>
        <population>The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.</population>
        <group_list>
          <group group_id="O1">
            <title>Candesartan</title>
            <description>Candesartan cilexetil 32 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Urinary Albumin Excretion Rate (UAER).</title>
          <description>An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient.</description>
          <population>The population was the Intention To Treat population which includes all randomized patients with any post-randomization data.</population>
          <units>log (Âµg/min)/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="711"/>
                <count group_id="O2" value="710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.510" lower_limit="0.487" upper_limit="0.534"/>
                    <measurement group_id="O2" value="0.543" lower_limit="0.520" upper_limit="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment, up to 5 years.</time_frame>
      <desc>The population used was the safety population which includes all patients who received at least 1 dose of randomized study drug and for whom any post-randomization data were available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Candesartan</title>
          <description>Candesartan cilexetil 32 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Lymphoid Tissue Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pericardial Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Coeliac Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Tooth Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Anogenital Warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pilonidal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cat Scratch Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Viral Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Foreign Body In Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Limb Crushing Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Traumatic Amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>HIV Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Shock Hypoglycaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Compartment Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm Of Thyroid Gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Skin Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Teratoma Benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Diabetic Autonomic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Leukoencephalomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Radiculitis Brachial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Intra-Uterine Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bartholin's Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Menstruation Irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Niklas Berglind, GPS Atacand</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+46 31 7766310</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

